Enhancer of Zest Homolog 2 (EZH2) as a therapeutic target in RhabdomyosarcomasDr Zoë Walters, University of Southampton
Development of GD2-specific Bi-specific T-cell Engagers (BiTEs) for treatment of neuroblastomaDr Karin Straathof, Institute of Child Health, University College London
BIOMarkers of Ependymomas in Children and Adolescents (BIOMECA) - Integrated Biological study within SIOP Ependymoma II trial organised by European Ependymoma BiologyProfessor Richard Grundy, Children’s Brain Tumour Research Centre, University of Nottingham
Accelerating Personalised Treatment for Children with Neuroblastoma with MRI BiomarkersDr Yann Jamin, Institute of Cancer Research
Novel therapies for MYCN-amplified neuroblastomaDr Helen Bryant, University of Sheffield
One of the greatest medical success stories of the last century is the amazing growth in the survival from childhood cancer. Fifty years ago, only a quarter of children diagnosed with cancer survived. Today, more than 80 per cent of young patients can be successfully treated.
However, cancer still claims the lives of around 250 children every year in the UK. And unfortunately the children who survive may be left with serious health and developmental problems as a result of the intensive treatments used to save their young lives.
Through our investment in research, we are taking forward our understanding of childhood cancer, to give new insights into ways of treating young patients with even the most difficult forms of cancer. We hope to drive up the survival rate still further whilst reducing the risk of harm.